Stocks of Johnson & Johnson (NYSE:JNJ) traded higher last session on Wall Street, up 1.64% to $162.30.
JNJ stock price is now 8.93% away from the 50-day moving average and 5.17% away from the 200-day moving average. The market capitalization of the company currently stands at $390.76B.
On November 15, 2024, Wolfe Research recently initiated its ‘Outperform’ rating on the stock quoting a target price of $190, while ‘Daiwa Securities’ rates the stock as ‘Neutral’
In other news, Schmid Timothy, EVP, WW Chair, MedTech sold 403 shares of the company’s stock on Feb 18 ’25. The stock was sold for $62,928 at an average price of $156.15. Upon completion of the transaction, the EVP, WW Chair, MedTech now directly owns 15,098 shares in the company, valued at $2.45 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 07 ’25, Exec VP, CFO Wolk Joseph J sold 13,015 shares of the business’s stock. A total of $2,002,878 was realized by selling the stock at an average price of $153.89. A total of 0.15% of the company’s stock is owned by insiders.
During the past 12 months, Johnson & Johnson has had a low of $140.68 and a high of $168.85. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 1.11, and a quick ratio of 0.86.
The net profit margin was 15.84% and return on equity was 20.06% for JNJ. The company reported revenue of $22.52 billion for the quarter, compared to $21.39 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.26 percent. For the current quarter, analysts expect JNJ to generate $21.65B in revenue.
